A novel cancer vaccine has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies. The vaccine targets KRAS mutations found in about 25% of solid tumors and drives about 90% of pancreatic cancers and 50% of colorectal cancers.
The Pew Charitable Trusts has funded 10 postdoctoral Latin American researchers for two years of biomedical science research in the US. They are exploring topics like brain tumor evolution, immune cell function, and nervous system repair.
Researchers have developed an AI system that can recognize the early warning stages of laryngeal cancer from voice recordings. By analyzing variations in tone, pitch, and volume, the AI can distinguish between voices with benign vocal fold lesions and those with cancer. The study's findings offer a promising breakthrough for non-invasi...
Researchers developed a neoAg mRNA-based vaccine that induces higher frequency of neoAg-specific cytotoxic T cells in mice, leading to tumor regression and eradication. The combination with anti-PD-1 therapy enhances antitumor efficacy, especially against peritoneal metastasis.
Researchers at City of Hope are investigating how wearable devices can detect and prevent long-term health risks in childhood cancer survivors. Yue Liao, a UT Arlington expert, is contributing to the review article, highlighting the potential of digital health tools to monitor daily fluctuations and behavior.
Researchers found that RSPO2 amplification is associated with poor outcomes in PC patients and promotes genes and signaling pathways associated with aggressive PC. The study highlights RSPO2 as a key driver of disease progression and opens new possibilities for treatment strategies.
Researchers at the University of Graz and the University of California, San Diego have developed a novel method to determine omega positions of lipids in complex biological samples. This breakthrough enables the study of biological mechanisms in unprecedented detail, particularly for inflammation-related diseases.
A groundbreaking cancer drug, KCL-HO-1i, has shown promise in making chemotherapy-resistant cancers more responsive to therapy by targeting a key defence mechanism used by tumours. In preclinical models, the drug has already demonstrated effectiveness in laboratory tests using mouse models of breast cancer.
Researchers synthesized AI-driven analysis of protein structures to predict drug interactions and optimize synergy. This fusion approach aims to solve drug resistance, reduce side effects, and guide personalized treatment in precision medicine.
The Lancet commission emphasizes the need for concrete goals to reduce hepatocellular carcinoma's growing disease burden. The authors propose a 2% annual reduction in age-standardized incidence rates and recommend evidence-based strategies to tackle viral hepatitis, alcohol consumption, environmental risk factors, and disparities in he...
The expansion of Huntsman Cancer Institute's proton therapy center will double treatment capacity and increase access to life-saving cancer care for patients in Utah, Idaho, Montana, Nevada, and Wyoming. The new center will enable the treatment of more patients and expand proton therapy options for certain types of cancers.
Researchers developed pH-responsive graphene-based nanocarriers that can target cancer cells, achieving efficient and safe drug delivery. The material's surface charge adapted to the acidic tumor environment, allowing it to bind and enter cancer cells while avoiding healthy tissues.
Researchers have identified a key architect of resistance to immunotherapy in bone metastases: reprogrammed neutrophils that suppress anti-tumor immune responses. DKK1 blockade restores the sensitivity of bone metastases to cancer immunotherapy, offering new potential targets for treatment.
Exosomes from tumors can promote cancer cell proliferation and angiogenesis, while also suppressing immune responses by delivering immunoinhibitory ligands. The review highlights the potential of exosome-based therapeutics to restore antitumor immunity.
Researchers are developing an AI imaging approach to distinguish between tumor progression and treatment effects in glioblastoma patients, promising to improve care and outcomes. The AI approach has already shown accuracy rates of up to 74% in initial testing.
A comprehensive analysis reveals how cancer cells hijack immune checkpoints on NK cells to disable the body's frontline defense system. Anti-TIGIT antibodies and CAR-NK innovation offer promising breakthroughs in liver cancer trials and acute myeloid leukemia treatment.
A study by Zhejiang University reveals how IL-6 reprograms PD-L1 expression in colorectal cancer stem cells, driving immunosuppressive effects. Dual-target therapy combining PI3K and STAT3 inhibitors shows promise in overcoming immunotherapy resistance.
A new deep learning model, MSI-SEER, achieves high accuracy in predicting microsatellite instability-high tumors and their responsiveness to immunotherapy. The model combines tumor MSI status with stroma-to-tumor ratio for highly accurate ICI response prediction.
A new study by the Germans Trias i Pujol Research Institute expands and optimizes 3D models to investigate colorectal cancer. The results show that different culture conditions affect spheroid morphology and compactness, highlighting the need for standardization.
Immune-related adverse events (irAEs) are a significant concern in cancer immunotherapy, arising from the overactivation of the immune system. Clinical characteristics include multi-organ involvement, heterogeneous onset times, and distinct toxicity profiles among different ICIs.
The symposium will feature talks by leading researchers on various aspects of cancer, including molecular discovery, clinical application, and population impact. Key findings include the exploration of genomic inequities and their impact on cancer disparities.
Researchers have discovered a novel microbial consortium called AUN that produces exceptional tumor eradication in both murine and human cancer models. The therapy exhibits high biocompatibility and minimal side effects, offering a long-awaited solution for immunocompromised patients.
Researchers at University of Alabama at Birmingham identify Gfi1 as a crucial regulator of exhausted CD8+ T cell subsets. Fine-tuning Gfi1 activity may prevent or reverse T cell exhaustion, bolstering immune checkpoint blockade therapy. The study suggests potential for improving cancer treatment and controlling chronic infections.
Researchers at UCLA have successfully created a continuous supply of functional T cells using genetically engineered stem cells. This breakthrough could lead to longer-lasting protection against cancer and potentially treat other diseases such as HIV or autoimmune disorders.
Researchers have developed a novel technology that can simultaneously silence two notoriously difficult-to-target cancer-related genes, KRAS and MYC. This innovation has the potential to treat cancers that have been challenging to treat, with significant implications for patients.
Researchers explore emerging role of extracellular RNAs in cancer diagnosis, prognosis, and treatment. These natural nanocarriers can reflect tumor behavior in real time and deliver targeted therapies.
Researchers found that automatically mailing a stool-based screening test resulted in the highest screening rates among adults aged 45-49. The study, which included over 20,000 patients, showed that this approach can encourage timely screening and potentially save lives.
Local-stage colorectal cancer incidence among US adults ages 45-49 increased by 50% between 2021 and 2022, with a steep rise in 2019-2022. Screening rates also increased during this period, driven by recommendations to start screening at age 45.
Researchers from Kumamoto University identified a genetic 'silencer' element that keeps the human T-cell leukemia virus type 1 (HTLV-1) in a dormant state, evading immune detection. This discovery offers hope for new therapeutic approaches to treat HTLV-1 and potentially even HIV.
Researchers have identified a protein called eIF2A that plays a crucial role in guiding melanoma cancer cells as they spread throughout the body. Targeting this protein could be a new approach to impede metastasis and improve healthcare outcomes for patients with melanoma.
Hollings researchers use natural language processing to identify primary cancer types in medical notes, improving treatment accuracy and personalized care. The AI model achieves high accuracy rates, outperforming standard medical codes in identifying primary cancer diagnoses.
A study using anonymized patient records from UC health centers found over 600 correlations between endometriosis and other conditions, including infertility, autoimmune disease, and certain cancers. The research supports the growing understanding of endometriosis as a multi-system disorder.
Research suggests that consuming high levels of sucralose can make cancer treatment less effective by disrupting the gut microbiome and altering T cell function. However, adding arginine or citrulline supplements to the diet may restore immunotherapy effectiveness in patients with melanoma and non-small cell lung cancer.
A study of ovarian tumor immune landscapes reveals four distinct immunologic subtypes, with those with T cells surviving longer and having better outcomes. The researchers also found that myeloid cells play a key role in reestablishing the immune landscape upon recurrence.
A global study found that cancer immunotherapies carry a hidden risk: cholestasis, a serious liver condition. Researchers urge aggressive monitoring of liver function, particularly in younger adults and women.
Researchers discovered that cancer cells have a defensive mechanism to repair DNA damage and survive physical stress by activating mitochondria to pump in extra ATP. This finding could lead to new therapeutic approaches by targeting the mechanism's underlying scaffold.
This book presents cutting-edge approaches to combat cancer, including exosomal delivery systems, CRISPR/Cas9 gene editing, and immunotoxin therapy. Natural compounds are also examined for their anticancer potential.
The THER web tool analyzes hypoxia-associated transcriptomic data without programming skills, presenting results via volcano plots, heatmaps, and tables. Experimental validation confirms THER's reliability, revealing broad impacts of hypoxia on drug efficacy across tumor types.
Recent AI-based models, such as Asian Prostate Cancer Artificial Intelligence and Galen Prostate, optimize screening and reduce unnecessary biopsies. These models use multimodal clinical parameters and convolutional neural networks to detect prostate cancer and identify aggressiveness of cancer cells.
Research reveals obesity's role in cancer development through mechanisms like chronic inflammation, hormonal disorders, and microbial dysbiosis. Lifestyle changes and targeted treatments hold potential in preventing obesity-related cancers.
Researchers at McMaster University have developed a promising new treatment for liver cancer by targeting metabolism in tumours. The discovery, published in Nature, shows that inhibiting an enzyme called ATP citrate lyase can enable the immune system to kill liver cancer cells, particularly through B cell-mediated responses.
Cancer-associated fibroblasts (CAFs) exhibit paradoxical effects on immunotherapy, sometimes hindering and other times helping to control tumors. Research identifies specific CAF subtypes that enhance or suppress immune cells, offering promising targets for therapies.
Researchers map the path from liver fibrosis to cancer, revealing how scarred liver tissue becomes a breeding ground for tumor growth. Key findings include the role of hepatic stellate cells and dysregulated signaling pathways in remodeling the liver into a pro-tumor environment.
A decade-long study reveals that the source of dietary fat, not adiposity itself, is the primary factor influencing tumor growth in obese mice. High-fat diets derived from animal fats compromise anti-tumor immunity and accelerate tumor growth, while plant-based fats have a neutral effect.
Researchers found that common respiratory infections like COVID-19 and influenza can awaken dormant breast cancer cells in the lungs, leading to a massive expansion of metastatic cells. The study suggests that individuals with a history of cancer may benefit from taking precautions against respiratory viruses.
Gemini achieved highest accuracy, followed by Claude-3-opus and GPT, with accuracy varying significantly across single-image tasks and continuous slices. Simplified prompts improved diagnostic performance, but Gemini and GPT struggled with normal image recognition.
A global analysis of CAR-T cell therapy found a significantly increased risk of developing secondary cancers, particularly T-cell lymphoma and myelodysplastic syndromes. The median onset of these cancers occurred much earlier in CAR-T recipients compared to those not receiving the treatment.
The CPADS web tool integrates data from GEO, TCGA, and GDSC databases to analyze gene expression changes, correlations between genes or drugs, and pathway enrichment in cancer samples. L1CAM was identified as a potential drug resistance target in non-small cell lung cancer through CPADS analysis.
A new study uses GenAI models to extract pathological features for lung adenocarcinoma grading and prognosis, achieving striking accuracy and consistency. The research team discovered 11 key histological features and 4 clinical variables that provide a comprehensive risk assessment for patients.
Researchers discovered that a type of HPV commonly found on the skin can directly cause a form of skin cancer called cutaneous squamous cell carcinoma when immune cells malfunction. The study's findings suggest that other people with defective T-cell responses may also be susceptible to cancer caused directly by beta-HPV.
Researchers have developed a predictive tool that can identify patients with nasopharyngeal carcinoma most likely to benefit from radiotherapy. The model uses transcriptomic data and machine learning to evaluate 113 algorithm combinations, identifying an 18-gene signature associated with radiosensitivity.
The American College of Chest Physicians has released a clinical guideline on the management of patients with early-stage non-small cell lung cancer. The guideline provides evidence-based recommendations for primary treatment and outlines three flowchart graphs outlining the recommended course of treatment based on patient risk. These ...
Researchers at Chiba University have developed novel microfluidic devices that incorporate microcones to detect and characterize circulating tumor cells in blood. The devices demonstrated highly selective capture of human breast and lung cancer cells, with high efficiency even at high flow rates.
A UCLA-led study found that while blood-based tests offer a convenient option for screening, only 49% of patients completed a follow-up colonoscopy within six months. The study's findings highlight the need for improved follow-up care to detect and treat colorectal cancer effectively.
Weill Cornell Medicine researchers found that PD-1 plays a critical role in forming long-term immune defenders in the skin. Blocking PD-1 too early can disrupt this process, leading to side effects. The study challenges current understanding of PD-1 and may impact cancer treatments.
Researchers will evaluate technology as a clinical tool for personalized cancer therapy, with potential to test various treatments on patient biopsies. The collaboration aims to obtain CAP/CLIA certification and conduct clinical studies to validate the utility of organoid-based assays.
Researchers analyzed data from over 10,000 solid tumor samples and found that more than 90 percent contained genetic changes that could guide treatment. The study identified biomarkers associated with approved therapies and rare mutations missed by simpler tests.
A new study found that immunotherapy may change the bone marrow environment where cancer cells live, potentially helping the immune system respond more effectively. Researchers tracked how the immune system interacts with cancer cells after treatment and noticed changes in cellular neighborhoods and cell communication.
A new silicone patch with star-shaped microneedles, called the ExoPatch, distinguishes melanoma from healthy skin in mice, capturing cancer biomarkers from exosomes. The test shows promise for early detection of the most aggressive form of skin cancer without a biopsy or blood draw.
Researchers have discovered a promising new approach to suppress the growth of aggressive cancers by targeting minor splicing, a specialized molecular process. By blocking minor splicing, cancer cells accumulate DNA damage and trigger cell death, while healthy cells remain largely unaffected.